Maegim한국어

휴온스

243070KOSDAQSector: Pharma & Biotech
₩25,550▲ 0.39%Market cap ₩306.1BAs of Jul 21, 2026 close · updated once daily
A
Grade A67.4 ptsTop 17% of 2,523 stocks
Financial strength
63.7
Growth momentum
54.4
Price attractiveness
80.9

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

63.7
How much debt does it carry relative to equity?
Debt-to-equity ratio
64.0%
✗ Below median · Top 60% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
169.6%
✗ Below median · Top 53% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
7.3%
✓ Above median · Top 23.3% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
11.4%
✓ Above median · Top 9.1% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

54.4
How much did revenue grow in a year?
Revenue growth (YoY)
5.2%
✗ Below median · Top 55.5% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
8.0%
✓ Above median · Top 39.8% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
14.9%
✓ Above median · Top 40.8% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
11.6%
✓ Above median · Top 46.5% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

80.9
Is the price expensive relative to earnings?
P/E (price-to-earnings)
7.2x
✓ Above median · Top 8.7% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.82x
✓ Above median · Top 29.5% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15